Literature DB >> 10225455

Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development.

B Lieubeau1, M F Heymann, F Henry, I Barbieux, K Meflah, M Grégoire.   

Abstract

In order to elucidate the role of myofibroblasts in tumor development, we compared fibroblastic reactions and their implications in the immune response in progressive and regressive rat colorectal-tumor models. Immunohistochemical analyses revealed that T lymphocytes and monocytes/macrophages were found outside progressive tumors that were surrounded by a large sheath of myofibroblasts. In vitro experiments using fibroblast- vs. myofibroblast-containing collagen gels showed that the mechanical properties of these tumor-activated myofibroblasts prevent penetration of T lymphocytes and macrophages within tumor nodules. These results indicate that tumor-activated myofibroblasts may prevent physical contact between cancer-cells and immune cells, an essential phenomenon for effective destruction of cancer cells. Successful immunotherapy against cancer should therefore include complementary treatments against these tumor-associated fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225455     DOI: 10.1002/(sici)1097-0215(19990517)81:4<629::aid-ijc20>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

2.  Tenascin immunoreactivity in the large bowel and the liver in patients with colorectal cancer.

Authors:  M V Gulubova; T Vlaykova
Journal:  Histochem J       Date:  2001-02

3.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

4.  Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer.

Authors:  Jingfang Gao; Gunnar Arbman; Ann Rearden; Xiao-Feng Sun
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

5.  In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis.

Authors:  Hideki Ueno; Eiji Shinto; Yojiro Hashiguchi; Hideyuki Shimazaki; Yoshiki Kajiwara; Takahiro Sueyama; Junji Yamamoto; Kazuo Hase
Journal:  Virchows Arch       Date:  2015-03-29       Impact factor: 4.064

6.  Desmoplasia in different degrees of invasion of carcinoma ex-pleomorphic adenoma.

Authors:  Vera Cavalcanti de Araújo; Cristiane Furuse; Patricia Ramos Cury; Albina Altemani; Venâncio Avancini Ferreira Alves; Ney Soares de Araújo
Journal:  Head Neck Pathol       Date:  2007-11-27

7.  Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis.

Authors:  Vassiliki Tzelepi; Petros Grivas; Zinovia Kefalopoulou; Haralabos Kalofonos; John N Varakis; Georgia Sotiropoulou-Bonikou
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

8.  Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Gaofeng Lu; Fuai Tang; Yiqing Liu; Guanglin Cui
Journal:  Virchows Arch       Date:  2009-10-21       Impact factor: 4.064

9.  Histological categorisation of fibrotic cancer stroma in advanced rectal cancer.

Authors:  H Ueno; A M Jones; K H Wilkinson; J R Jass; I C Talbot
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 10.  Positive and negative influence of the matrix architecture on antitumor immune surveillance.

Authors:  Elisa Peranzoni; Ana Rivas-Caicedo; Houcine Bougherara; Hélène Salmon; Emmanuel Donnadieu
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.